Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK-Style Insurance Risk-Sharing Could Affect Medicaid Rebates, Part B ASPs

Executive Summary

U.S. biopharma manufacturers should be cautious about importing the British National Institute for Health and Clinical Excellence's approaches to reimbursement risk-sharing, as such schemes could have unanticipated consequences for obligations such as Medicaid rebates

You may also be interested in...



Revlimid gets NICE nod

UK's National Institute for Health and Clinical Excellence makes a preliminary positive recommendation for use of Celgene's Revlimid (lenalidomide) as a second-line therapeutic for multiple myeloma. After receiving the recommendation, the National Health Service is expected to make a final decision during the second quarter. If NHS agrees, it would fully fund use of oral Revlimid, given along with dexamethasone, for 26 treatment cycles of 28 days per cycle (normally two years). Celgene says it will pick up the tab for UK patients who choose to remain on the drug for longer. In the U.S., Revlimid is approved for treatment of MM patients who have received at least one prior therapy and for transfusion-dependent anemia in those with myelodysplastic syndromes. It also is listed on several compendia and used off-label in newly diagnosed MM patients (1"The Pink Sheet," Dec. 15, 2008, p. 11). The biologic hit $1.3 billion in worldwide sales in 2008. Celgene plans to file in the U.S. for approval as a front-line therapy for MM in 2009

Velcade Rebate Scheme In U.K. Sets Up Broader Cost-Effectiveness Review

An innovative cost-sharing arrangement in which Johnson & Johnson will rebate the cost of the cancer drug Velcade (bortezomib) when patients have a minimal response will be implemented in the U.K. by early 2008

Medicare Part B Rates For Bundled Drugs Might Be Improved With “Exceptions” Process – MedPAC

CMS should consider a process to allow revisions of Part B average sales prices for drugs sold through bundled arrangements, to enhance the accuracy of ASPs, the advisory panel group suggests to agency.

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel